NO20053310L - Fremgangsmate og sammensetning til a behandle engstelse. - Google Patents

Fremgangsmate og sammensetning til a behandle engstelse.

Info

Publication number
NO20053310L
NO20053310L NO20053310A NO20053310A NO20053310L NO 20053310 L NO20053310 L NO 20053310L NO 20053310 A NO20053310 A NO 20053310A NO 20053310 A NO20053310 A NO 20053310A NO 20053310 L NO20053310 L NO 20053310L
Authority
NO
Norway
Prior art keywords
active ingredient
patient
pyridinyl
administered
treating anxiety
Prior art date
Application number
NO20053310A
Other languages
English (en)
Other versions
NO20053310D0 (no
Inventor
Janet Codd
Bernard Beer
Original Assignee
Nascime Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nascime Ltd filed Critical Nascime Ltd
Publication of NO20053310D0 publication Critical patent/NO20053310D0/no
Publication of NO20053310L publication Critical patent/NO20053310L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Abstract

I 5 Det er beskrevet en fremgangsmåte til å behandle engstelse i en pasient ved oral administrering til nevnte pasient av en daglig dose av den aktive ingrediens, 1-pyridinyl[7-(4-pyridinyl)pyrazol[1,5-a]-pyrimidin-3-yl]metanon eller dets farmasøytisk akseptable salter, spesielt Ocinaplonin, i to separate adskilte administreringer, hvori en første porsjon blir administrert i en forsinket frigjøringsform og den gjenværende porsjon blir administrert i en øyeblikkelig frigjøringsform for å opprettholde blodnivåene av denne aktive ingrediens på terapeutisk relevante nivåer for å opprettholde anti-engstelsesvirkningen i pasienten under periodene mellom administreringene av den aktive ingrediens, så vel som farmasøytiske sammensetninger som inneholder denne aktive ingrediens for administrering i sammenheng med ovennevnte fremgangsmåte.
NO20053310A 2002-12-04 2005-07-04 Fremgangsmate og sammensetning til a behandle engstelse. NO20053310L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43074002P 2002-12-04 2002-12-04
PCT/US2003/037714 WO2004050019A2 (en) 2002-12-04 2003-11-25 Method and compositions for treating anxiety

Publications (2)

Publication Number Publication Date
NO20053310D0 NO20053310D0 (no) 2005-07-04
NO20053310L true NO20053310L (no) 2005-08-29

Family

ID=32469522

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053310A NO20053310L (no) 2002-12-04 2005-07-04 Fremgangsmate og sammensetning til a behandle engstelse.

Country Status (12)

Country Link
US (1) US20040192706A1 (no)
EP (1) EP1581230A2 (no)
JP (1) JP2006509789A (no)
KR (1) KR20050085386A (no)
CN (1) CN1720048A (no)
AU (1) AU2003297559A1 (no)
BR (1) BR0316192A (no)
CA (1) CA2507609A1 (no)
NO (1) NO20053310L (no)
PL (1) PL377357A1 (no)
RU (1) RU2005120749A (no)
WO (1) WO2004050019A2 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155170A2 (en) * 2007-06-08 2010-02-24 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4521422A (en) * 1983-06-23 1985-06-04 American Cyanamid Company Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US6399621B1 (en) * 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration

Also Published As

Publication number Publication date
EP1581230A2 (en) 2005-10-05
PL377357A1 (pl) 2006-02-06
NO20053310D0 (no) 2005-07-04
BR0316192A (pt) 2005-10-11
JP2006509789A (ja) 2006-03-23
CN1720048A (zh) 2006-01-11
WO2004050019A2 (en) 2004-06-17
WO2004050019A9 (en) 2012-03-22
AU2003297559A1 (en) 2004-06-23
US20040192706A1 (en) 2004-09-30
KR20050085386A (ko) 2005-08-29
RU2005120749A (ru) 2006-01-20
WO2004050019A3 (en) 2004-08-12
CA2507609A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
RU2130776C1 (ru) Пиразолпиримидиноны для лечения импотенции
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
SE0201669D0 (sv) New formulation and use thereof
UA94916C2 (ru) Композиция тразодона для введения один раз в день
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO2003045437A8 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NZ517367A (en) Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flashes
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MD523G2 (ro) Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
NO20004931L (no) Anvendelse av dexmedetomidin til sedering pÕ intensivavdeling
AU2002366567B2 (en) Use of an H1 antagonist and a safe steroid to treat rhinitis
WO2004096118B1 (en) Composition for improving cognition and memory
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
AU2003229724B2 (en) Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
JP2000198734A (ja) 胃運動性減弱および関連疾患の治療のための運動性増強薬
NO20053310L (no) Fremgangsmate og sammensetning til a behandle engstelse.
EE200200695A (et) (-)-5-(3-klorofenüül)-alfa-(4-klorofenüül)-alfa-(1-metüül-1H-imidasool-5-üül)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
WO2002056867A3 (en) Extended release pharmaceutical compositions containing beta-lactam antibiotics
EP3345603B1 (en) Iloperidone metabolite for use in the treatment of psychiatric disorders
JP2004520279A (ja) 早発射精の治療